Advertisement
Advertisement
U.S. markets open in 3 hours 5 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Soligenix, Inc. (SNGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5413-0.0126 (-2.27%)
At close: 04:00PM EDT
0.5390 -0.00 (-0.42%)
After hours: 04:51PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close0.5539
Open0.5900
Bid0.0000 x 1000
Ask0.0000 x 2200
Day's Range0.5160 - 0.6100
52 Week Range0.3800 - 1.3200
Volume1,321,462
Avg. Volume171,685
Market Cap23.303M
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-0.3490
Earnings DateAug 11, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SNGX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Soligenix, Inc.
    Analyst Report: Emergent BioSolutions IncEmergent BioSolutions makes vaccines and other products intended to protect civilian and military populations from emerging infectious diseases and chemical, biological or nuclear attacks. The company generates its revenue from product sales of its smallpox vaccine (ACAM2000), its anthrax vaccines (BioThrax and AV7909), and its Narcan nasal spray (a treatment for opioid overdoses), as well as from contract development and manufacturing services and contracts and grants. The USG is the company's primary customer, and provides EBS with significant product development funding. EBS shares are a component of the S&P 400 Index. The company has approximately 2,500 employees.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
Advertisement
Advertisement